Valion Bio, Inc. Selling, General and Administrative Expense
Valion Bio, Inc. (VBIO) reported Selling, General and Administrative Expense of $3.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-14
- Valion Bio, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $3.72M, a 263.64% increase year-over-year.
- Valion Bio, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $3.78M, a 262.76% increase year-over-year.
- Valion Bio, Inc. selling, general and administrative expense for the quarter ending 2026-03-30 was $3.78M, a 262.76% increase year-over-year.
- Valion Bio, Inc. selling, general and administrative expense for the quarter ending 2025-06-30 was $1.02M.
- Valion Bio, Inc. selling, general and administrative expense for fiscal 2025 was $4.77M, a 50.71% increase from fiscal 2024.
- Valion Bio, Inc. selling, general and administrative expense for fiscal 2024 was $3.16M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|
| 2026-06-30 | $3.72M 10-Q · filed 2026-08-14 | $7.50M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $3.78M 10-Q · filed 2026-05-14 | ||
| 2026-03-30 | $3.78M 10-Q · filed 2026-05-14 | ||
| 2025-12-31 | $4.77M 10-K · filed 2026-03-30 | ||
| 2025-06-30 | $1.02M 10-Q · filed 2026-08-14 | $2.06M 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $1.04M 10-Q · filed 2026-05-14 | ||
| 2024-12-31 | $3.16M 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |